WO1998058086A2 - Nucleic acid primers and probes for detecting hiv-1 and hiv-2 - Google Patents
Nucleic acid primers and probes for detecting hiv-1 and hiv-2 Download PDFInfo
- Publication number
- WO1998058086A2 WO1998058086A2 PCT/US1998/011652 US9811652W WO9858086A2 WO 1998058086 A2 WO1998058086 A2 WO 1998058086A2 US 9811652 W US9811652 W US 9811652W WO 9858086 A2 WO9858086 A2 WO 9858086A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- primer
- seq
- hiv
- nos
- probe set
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
Definitions
- the present invention relates to HIV.
- the-invention relates to oligonucleotides and methods for detecting HIV 1 and HIV 2.
- Viruses classified as HIV contain RNA as their genetic information and the infectivity of HIV depends upon the virus's ability to insert its genetic information into the DNA of a host.
- an HIV virus In order to insert its genetic information and therefore successfully infect a host, an HIV virus must convert its genetic material (RNA) into DNA so that the HIV genetic information is compatible with that of the host.
- RNA genetic material
- HIV is successful at converting its RNA into DNA, given the prevalence of AIDS.
- the virus may successfully convert RNA into DNA, the conversion is seldom accurate. In other words, the DNA copy of the viral RNA is not always exact and the DNA copy can diverge from the viral RNA by several base pairs.
- HIV HIV 1
- HIV 2 HIV 2
- group M which is further classified into subtypes A-F
- group O subtypes A-E
- Subtypes of HIV 1 and HIV 2 are broken down even further into categories to numerous to mention in this context.
- the genetic variability of the virus can be attributed to the inefficiency with which the virus converts its RNA into DNA, as mentioned above.
- Another theory concerning the genetic variability of the virus is that hosts can be infected with multiple different populations of HIV (which as mentioned above, can arise out of an infection by a single virus) and through the course of replication and packaging of the viral genetic information, pieces of one viral genome can be recombined with pieces of another viral genome. Hence, upon packaging of the recombined genome, a genetically distinct virus is formed. Regardless of the manner by which the virus mutates, it is clear that viruses known as HIV have genomes that are highly mutable and are therefore constantly changing. This presents those searching for methods of detecting the virus based upon its genetic information with a constantly moving target.
- the present invention provides reagents useful for detecting HIV (that is the various subtypes of HIV 1 and HIV 2) based upon the genetic information of these viruses.
- the reagents are in the form of primer and probe sets which can be employed according to nucleic acid amplification procedures to specifically and sensitively detect various subtypes of HIV 1 and HIV 2.
- the primer/probe sets herein provided comprise two primer sequences and one probe sequence and are employed according to a reverse transcriptase (RT) PCR format.
- Primer/probe sets of the invention which can be employed to detect HIV 1 are designated herein as primer/probe set 1 (SEQ. ID. NOs.
- primer/probe set 2 SEQ. ID. NOs. 5, 6 and 7
- primer/probe set 3 SEQ. ID. NOs. 8, 9, 10 and 1 1
- primer/probe set 4 SEQ. ID. NOs. 12, 13 and 14
- the method for detecting HIV will generally comprise the steps of (a) forming a reaction mixture comprising nucleic acid amplification reagents, at least one primer/probe set mentioned above, and a test sample containing an HIV target sequence; (b) subjecting the mixture to amplification conditions to generate at least one copy of a nucleic acid sequence complementary to the target sequence; (c) hybridizing the probe to the nucleic acid sequence complementary to the target sequence, so as to form a hybrid comprising the probe and the nucleic acid sequence complementary to the target sequence; and (d) detecting the hybrid as an indication of the presence of HIV in the test sample.
- the preferred RT PCR format will comprise the same steps as mentioned above but the amplification reagents will comprise an enzyme having reverse transcriptase activity.
- step (b) can be repeated multiple times to increase the number of target sequence copies. It will be understood by those skilled in the art that step (b) can be repeated through thermal cycling the reaction mixture.
- the primer/probe sets provided herein comprise two primers and at least one probe. These primer/probe sets can be employed according to nucleic acid amplification techniques. Hence, the primers in any particular primer/probe set can be employed to amplify a target sequence. In most cases, the probe hybridizes to the copies of the target sequence generated by one of the primers and generally facilitates detecting any copies of the target sequence generated during the course of the amplification reaction. All of the primer/probe sets can be employed according to nucleic acid amplification procedures to specifically and sensitively detect HIV 1 group M and group O, as well as the various subtypes of HIV 2. Primer/probe sets for detecting HIV 1 subtypes are presented below in Table 1 and primer/probe sets for detecting HIV 2 subtypes are presented in Table 2 below. TABLE 1
- primers included in the primer/probe sets can be used to prime synthesis of copies of an HIV 1 target sequence in the case of SEQ ID NOs. ' 2, 3, 5, 6, 8, 9, 12, and 13; and copies of an HIV 2 target sequence in the case of SEQ ID NOs. 16, 17, 19, 20, 23 and 24.
- the remaining SEQ ID NOs. (SEQ ID NOs. 4, 7, 10, 11 , 14, 18, 21 , and 22), hybridize with the amplification products of either or both of the primer sequences found in the same primer/probe set.
- primer/probe set 6 is specific for HIV 2 insofar as SEQ. ID. NOs. 19 and 20 prime synthesis of the HIV 2 target sequence and SEQ. ID. NOs. 21 and 22 hybridize with the amplification products produced by SEQ. ID. NOs. 19 and 20.
- the probe sequences are also specific for the various subtypes of HIV 1 or HIV 2.
- Primer sequences generally comprise deoxyribonucleic acid (DNA), or ribonucleic acid (RNA).
- Probe sequences on the other hand may comprise DNA, RNA or nucleic acid analogs such as uncharged nucleic acid analogs including but not limited to peptide nucleic acids (PNAs) which are disclosed in International Patent Application WO 92/20702 or morpholino analogs which are described in U.S. Patents Numbered 5,185,444, 5,034,506, and 5,142,047 all of which are herein incorporated by reference.
- PNAs peptide nucleic acids
- Such sequences can routinely be synthesized using a variety of techniques currently available.
- a sequence of DNA can be synthesized using conventional nucleotide phosphoramidite chemistry and the instruments available from Applied Biosystems, Inc, (Foster City, CA); DuPont, (Wilmington, DE); or Milligen, (Bedford, MA).
- the sequences can be labeled using methodologies well known in the art such as described in U.S. Patent Applications Numbered 5,464,746; 5,424,414; and 4,948,882 all of which are herein incorporated by reference.
- label means a molecule or moiety having a property or characteristic which is capable of detection.
- a label can be directly detectable, as with, for example, radioisotopes, fluorophores, chemiluminophores, enzymes, colloidal particles, fluorescent microparticles and the like; or a label may be indirectly detectable, as with, for example, specific binding members. It will be understood that directly detectable labels may require additional components such as, for example, substrates, triggering reagents, light, and the like to enable detection of the label.
- indirectly detectable labels are used, they are typically used in combination with a "conjugate".
- a conjugate is typically a specific binding member which has been attached or coupled to a directly detectable label.
- Coupling chemistries for synthesizing a conjugate are well known in the art and can include, for example, any chemical means and/or physical means that does not destroy the specific binding property of the specific binding member or the detectable property of the label.
- specific binding member means a member of a binding pair, i.e., two different molecules where one of the molecules through, for example, chemical or physical means specifically binds to the other molecule.
- other specific binding pairs include, but are not intended to be limited to, avidin and biotin; haptens and antibodies specific for haptens; complementary nucleotide sequences; enzyme cofactors or substrates and enzymes; and the like.
- test sample means anything suspected of containing an HIV target sequence.
- the test sample is or can be derived from any biological source, such as for example, blood, ocular lens fluid, cerebral spinal fluid, milk, ascites fluid, synovial fluid, peritoneal fluid, amniotic fluid, tissue, fermentation broths, cell cultures and the like.
- the test sample can be used (i) directly as obtained from the source or (ii) following a pre-treatment to modify the character of the sample.
- test sample can be pre-treated prior to use by, for example, preparing plasma from blood, disrupting cells or viral particles, preparing liquids from solid materials, diluting viscous fluids, filtering liquids, distilling liquids, concentrating liquids, inactivating interfering components, adding reagents, purifying nucleic acids, and the like.
- target sequence means a nucleic acid sequence that is detected, amplified, or both amplified and detected using the primer/probe sets herein provided. Additionally, while the term target sequence is sometimes referred to as single stranded, those skilled in the art will recognize that the target sequence may actually be double stranded. Thus, in cases where the target is double stranded, primer sequences of the present invention will amplify both strands of the target sequence.
- the primer sequences of any particular primer/probe set can be used as amplification primers according to nucleic acid amplification procedures well known in the art.
- Such reactions include, but are not intended to be limited to, the polymerase chain reaction (PCR) described in U.S. Patents 4,683,195 and 4,683,202, the ligase chain reaction (LCR) described in EP-A-320 308, and gap LCR (GLCR) described in U.S. Patent No. 5,427,930 all of which are herein incorporated by reference.
- PCR polymerase chain reaction
- LCR ligase chain reaction
- GLCR gap LCR
- the target sequence may indeed be DNA
- the primer/probe sets may be employed according to an "RT PCR" format which is described in U.S. Patents numbered 5,322,770 and 5,310,652 both of which are herein incorporated by reference.
- the RT PCR format provides a method of transcribing a strand of DNA from an RNA target sequence.
- the copied DNA strand transcribed from the RNA target is commonly referred to as "cDNA" which then can serve as a template for amplification by any of the methods mentioned above.
- the primer/probe sets are employed in the "oligonucleotide hybridization PCR" (variably referred to herein as “OH PCR”) amplification reaction as described in U.S. Patent Application Serial No. 08/514,704, filed August 14, 1995, that is herein incorporated by reference.
- the reagents employed in the preferred method comprise at least one primer/probe set (designated herein as primer/probe sets 1 -8), as well as other reagents for performing an amplification reaction.
- “Other reagents for performing an amplification reaction” or “nucleic acid amplification reagents” include reagents which are well known and may include, but are not limited to, an enzyme having polymerase activity, enzyme cofactors such as magnesium; salts; nicotinamide adenine dinucleotide (NAD); and deoxynucleotide triphosphates (dNTPs) such as for example deoxyadenine triphosphate, deoxyguanine triphosphate, deoxycytosine triphosphate and deoxythymine triphosphate.
- enzyme cofactors such as magnesium
- salts such as nicotinamide adenine dinucleotide (NAD); and deoxynucleotide triphosphates (dNTPs) such as for example deoxyadenine triphosphate, deoxyguanine triphosphate, deoxycytosine triphosphate and deoxythymine triphosphate.
- dNTPs deoxynucle
- the preferred method generally comprises the steps of (a) forming a reaction mixture comprising nucleic acid amplification reagents, at least one primer/probe set of the present invention, and a test sample suspected of containing a target sequence; (b) subjecting the mixture to amplification conditions to generate at least one copy of a nucleic acid sequence complementary to the target sequence; (c) hybridizing the probe to the nucleic acid sequence complementary to the target sequence, so as to form a hybrid comprising the probe and the nucleic acid sequence complementary to the target sequence; and (d) detecting the hybrid as an indication of the presence of the target sequence (HIV) in the sample.
- step (b) of the above method can be repeated several times prior to step (c) by thermal cycling the reaction mixture between 10 and 100 times, more typically between 20 and 60 times, as is well known in the art.
- Amplification conditions are defined generally as conditions which promote annealing and extension of one or more nucleic acid sequences. It is well known in the art that such annealing is dependent in a rather predictable manner on several parameters, including temperature, ionic strength, sequence length, complementarity, and G:C content of the sequences. For example, lowering the temperature in the environment of complementary nucleic acid sequences promotes annealing. For any given set of sequences, melt temperature, or Tm, can be estimated by any of several known methods. Typically, diagnostic applications utilize hybridization temperatures which are close to (i.e. within 10°C) the melt temperature.
- Ionic strength or "salt" concentration also impacts the melt temperature, since small cations tend to stabilize the formation of duplexes by negating the negative charge on the phosphodiester backbone. Typical salt concentrations depend on the nature and valency of the cation but are readily understood by those skilled in the art.
- high G:C content and increased sequence length are also known to stabilize duplex formation because G:C pairings involve 3 hydrogen bonds where A:T pairs have just two, and because longer sequences have more hydrogen bonds holding the sequences together.
- a high G:C content and longer sequence lengths impact the hybridization conditions by elevating the melt temperature.
- the G:C content and length will be known and can be accounted for in determining precisely what hybridization conditions will encompass. Since ionic strength is typically optimized for enzymatic activity, the only parameter left to vary is the temperature. Generally, the hybridization temperature is selected close to or at the Tm of the primers or probe. Thus, obtaining suitable hybridization conditions for a particular primer/probe set is well within ordinary skill of one practicing this art.
- the probe sequence has a lower melt temperature than the primer sequences so that upon placing the reaction mixture under amplification conditions copies of the target sequence or its complement (variably referred to as an amplicon) are produced at temperature above the Tm of the probe.
- copies of the target sequence or its complement are produced at temperature above the Tm of the probe.
- the rate of temperature reduction from the denaturation temperature down to a temperature at which the probes will bind to single stranded copies is preferably quite rapid for example between about 8 minutes to about 15 minutes, preferably less than 2 minutes.
- Such a rapid cooling favors hybrid formation between the copies of the target sequence and the probe rather than, for example, hybrid formation between complementary strands of the amplicon.
- primer sequences are labeled with either a capture label or a detection label.
- the probe sequence is used to hybridize with the sequence generated by the primer sequence, and typically hybridizes with a sequence that does not include the primer sequence.
- the probe sequence is also labeled with either a capture label or a detection label with the caveat that when the primer is labeled with a capture label the probe is labeled with a detection label and vice versa.
- Detection labels have the same definition as "labels" previously defined and “capture labels” are typically used to separate extension products, and probes associated with any such products, from other amplification reactants. Specific binding members (as previously defined) are well suited for this purpose.
- probes used according to this method are preferably blocked at their 3' ends so that they are not extended under hybridization conditions.
- Methods for preventing extension of a probe are well known and are a matter of choice for one skilled in the art.
- adding a phosphate group to the 3' end of the probe will suffice for purposes of blocking extension of the probe.
- the differential labels (i.e. capture and detection labels) on the copy sequence and probe sequence can be used to separate and detect such hybrids.
- detection is performed according to the protocols used by the commercially available Abbott LCx® instrumentation (Abbott Laboratories; Abbott Park, IL).
- the target sequence may be DNA or the target sequence may be imbedded within the HIV genome and therefore the target sequence may be in the form of RNA.
- the target sequence is part of the HIV genome, it is preferable to include an enzyme having reverse transcriptase activity as part of the so-called nucleic acid amplification reagents to enable production of cDNA for subsequent amplification.
- the primer sequences also serve as primers for cDNA synthesis.
- HIV 1 and HIV 2 can be detected simultaneously in a single reaction using a combination of two primer/probe sets (i.e. one selected from the HIV 1 specific primer/probe sets and the other selected from the HIV 2 specific primer/probe sets).
- a test sample could be contacted with primer/probe sets 1 and 8 along with amplification reagents, which may or may not include an enzyme having reverse transcriptase activity, to amplify and detect the presence of HIV 1 and HIV 2 in a test sample.
- the oligonucleotides of the present invention also can be provided as part of a kit useful for detecting HIV 1 or HIV 2.
- kits comprise one or more suitable containers containing one or more primer/probe sets according to the present invention, an enzyme having polymerase activity, deoxynucleotide triphosphates and, optionally, an enzyme having reverse transcriptase activity.
- an enzyme having polymerase activity e.g., adenosine triphosphate
- deoxynucleotide triphosphates e.g., glycerol
- SEQUENCE ID NO. 2 SEQUENCE ID NO. 3
- SEQUENCE ID NO. 4 SEQUENCE ID NO. 5
- SEQUENCE ID NO. 6 SEQUENCE ID NO.7
- SEQUENCE ID NO. 8 SEQUENCE ID NO.9
- SEQUENCE ID NO. 10 SEQUENCE ID NO. 11
- SEQUENCE ID NO. 12 SEQUENCE ID NO. 13, SEQUENCE ID NO. 14, SEQUENCE ID NO. 16, SEQUENCE ID NO. 17, SEQUENCE ID NO. 18, SEQUENCE ID NO. 19, SEQUENCE ID NO. 20, SEQUENCE ID NO. 21 , SEQUENCE ID NO.22, SEQUENCE ID NO.23 and SEQUENCE ID NO. 24.
- SEQUENCE ID NO. 2 SEQUENCE ID NO. 3
- SEQUENCE ID NO.4 SEQUENCE ID NO. 5
- SEQUENCE ID NO. 6 SEQUENCE ID NO.7, SEQUENCE ID NO. 8, SEQUENCE ID NO. 9, SEQUENCE ID NO. 10, SEQUENCE ID NO. 11, SEQUENCE ID NO. 12, SEQUENCE ID NO. 13 and SEQUENCE ID NO. 14 are specific for HIV-1.
- a representative target sequence from HIV-1 (subtype B, strain MN) is designated herein as SEQ ID NO. 1.
- SEQUENCE ID NO. 16 SEQUENCE ID NO.
- SEQUENCE ID NO. 17 SEQUENCE ID NO. 18, SEQUENCE ID NO. 19, SEQUENCE ID NO. 20, SEQUENCE ID NO. 21 , SEQUENCE ID NO. 22, SEQUENCE ID NO. 23 and SEQUENCE ID NO. 24 are specific for HIV-2.
- a representative target sequence from HIV-2 (subtype A, strain NIH-Z) is designated herein as SEQ ID NO. 15. All primers and probes are consensus sequences derived from 31 HIV-1 group M (subtypes A, B and D) and group O isolates and 14 HIV-2 isolates of both the A and B subtypes for the HIV-2 sequences.
- SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 12 and SEQ ID NO. 13 are used as consensus amplification primers specific for the HIV-1 target sequence.
- SEQ ID NO. 4, SEQ ID NO. 7, SEQ ID NO. 10, SEQ ID NO. 11 and SEQ ID NO. 14 are used as consensus internal hybridization probes for the HIV-1 amplification product.
- SEQ ID NO. 16, SEQ ID NO. 17, SEQ ID NO. 19, SEQ ID NO. 20, SEQ ID NO. 23 and SEQ ID NO. 24 are used as consensus amplification primers specific for the HIV-2 target sequence and SEQ ID NO. 18, SEQ ID NO. 21 and SEQ ID NO. 22 are used as consensus internal hybridization probes for the HIV-2 amplification product.
- Consensus primers were designed to detect all known HIV-1 or HIV-2 subtypes by oligonucleotide hybridization PCR. These primers were SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 12 and SEQ ID NO. 13 for HIV-1 , and SEQ ID NO. 16, SEQ ID NO. 17, SEQ ID NO. 19, SEQ ID NO. 20, SEQ ID NO. 23 and SEQ ID NO. 24 for HIV-2.
- Primer sequences were synthesized using standard oligonucleotide synthesis methodology and haptenated with adamantane at their 5' ends using standard cyanoethyl phosphoramidite coupling chemistry as described in U.S. Patent No. 5,424,414 incorporated herein by reference.
- Probes were designed to hybridize with the amplified HIV target sequence by oligonucleotide hybridization. These probes were SEQ ID NO. 4, SEQ ID NO. 7, SEQ ID NO. 10, SEQ ID NO. 11 and SEQ ID NO. 14 for HIV-1 , and SEQ ID NO. 18, SEQ ID NO. 21 and SEQ ID NO. 22 for HIV-2. Probe sequences were synthesized using standard oligonucleotide synthesis methodology and haptenated with 2 carbazoles at the 5' end using standard cyanoethyl phosphoramidite coupling chemistry as described in U.S. Patent No. 5,464,746 (herein incorporated by reference), and blocked with phosphate at the 3' end.
- HIV-1 consensus primer/probe sets were evaluated: set #1 used SEQ ID NOs. 2 and 3 as primers and SEQ ID NO. 4 as probe, set #2 used SEQ ID NOs. 5 and 6 as primers and SEQ ID NO. 7 as probe, set #3 used SEQ ID NOs. 8 and 9 as primers and SEQ ID NOs. 10 and 11 as probes, and set #4 used SEQ ID NOs. 12 and 13 as primers and SEQ ID NO. 14 as probe. All sequences were prepared as described in Example 1.
- RNA samples Dilutions of the purified HIV-1 RNA were reverse transcribed, PCR amplified and detected using the four HIV-1 consensus primer/probe sets in separate reactions.
- RT-PCR was performed using 50 mM Bicine, pH 8.25, 115 mM potassium acetate, 0.5 mM EDTA, 8% glycerol, 10 ⁇ g/ml bovine serum albumin (BSA) and 0.02% sodium azide.
- BSA bovine serum albumin
- Recombinant Thermus thermophilus polymerase was used at a concentration of 5 units/reaction, with dNTPs (dATP, dGTP, dTTP and dCTP) present at a final concentration of 0.15 mM each.
- Primers were used at a concentration of 500 nM each, and probes at a concentration of 10 nM each.
- a final concentration of 2.5 mM MnCI 2 was used in a total reaction volume of 0.2 ml, with sample volume of 25 to 50 ⁇ l.
- the negative control was composed of 100 ng of ribosomal RNA/reaction.
- Reaction mixtures were reverse transcribed and amplified in a Perkin-Elmer 480 Thermal Cycler. Reaction mixtures were first incubated at 62°C for 30 minutes to reverse transcribe the RNA, followed by 30 seconds at 94°C. PCR amplification was then initiated through a touchdown or step-down protocol to aid in the stringency of the reaction in the early stages of amplification.
- Reaction products were detected on the Abbott LCx® system (available from Abbott Laboratories, Abbott Park, IL).
- a suspension of anti-carbazole antibody coated microparticles and an anti-adamantane antibody/alkaline phosphatase conjugate (all of which are commercially available from Abbott Laboratories, Abbott Park, IL) were used in conjunction with the LCx® to capture and detect the reaction products.
- the enzyme substrate used was methyl-umbelliferyl phosphate (MUP), with the rate of conversion of MUP to MU (methyl-umbelliferone) measured and reported as counts/second/second (c/s/s).
- Three different HIV-2 consensus primer/probe sets were evaluated: set #5 used SEQ ID NOs. 16 and 17 as primers and SEQ ID NO. 18 as probe, set #6 used SEQ ID NOs. 19 and 20 as primers and SEQ ID NO. 22 as probe (although SEQ ID NO 21 could also have been employed as a probe alone or in combination with SEQ ID NO. 22), and set #7 used SEQ ID NOs. 20 and 23 as primers and SEQ ID NO. 21 as probe. All sequences were prepared as described in Example 1.
- Reaction mixtures were prepared, reverse transcribed, amplified and detected using the three HIV-2 consensus primer/probe sets in separate reactions, as described in Example 2.
- Results presented in TABLE 4 show detection of HIV-2 to concentrations as low as 1 molecule/assay using HIV-2 consensus primer/probe sets 5 and 6, and detection of 100 molecules/assay using HIV-2 primer/probe set 7.
- Example 4 HIV-1 Subtype Detection The genetic divergence of HIV is the most challenging aspect to detection. There is a need for assays that accurately detect all subtypes, including the most widely divergent "O" subtype. Serum samples were obtained from Digene (Silver Spring, MD) of HIV-1 subtypes A through F, and two isolates of HIV-1 , subtype O. Viral RNA was extracted and purified from each isolate using Qiagen columns and methodology as described by the manufacturer (Qiagen, Frankfurt, Germany). RNA was quantitated in viral RNA copies per milliliter and ten-fold serial dilutions were made into 1 ng/ ⁇ l ribosomal RNA for detection. Table 5 shows the amount of RNA (molecules/assay) used per reaction at each sample dilution for each subtype.
- HIV-1 primer/probe set #1 detected all HIV-1 subtypes tested in Table 6 above, including the widely divergent O subtypes, in a sensitivity range between 100 and 1 molecules/assay.
- HIV-1 primer/probe set #2 detected all HIV-1 subtypes tested in Table 7 above with a sensitivity similar to that of HIV-1 primer/probe set #1.
- HIV-1 primer/probe set #3 detected 5 of the 6 HIV-1 subtypes tested in Table 8 above with a sensitivity of approximately 200 mol/assay.
- HIV-1 primer/probe set #4 detected 4 of the 6 HIV-1 subtypes tested in Table 9 above with a sensitivity of between 2000 to 200 mol/assay.
- Example 5 Specificity of HIV-1 and HIV-2 Primer/Probe Sets The specificity of HIV-1 primer/probe sets #1 and #2 was assessed against RNA which was extracted and purified from HIV-1 subtype B (strains MN and 3B) and HIV-2 serum samples as in Example A The two different HIV-1 consensus primer/probe sets were used in separate reactions to reverse transcribe, amplify and detect 1 :10 dilutions of the sample RNA as described in Example 2. As shown in Table 10, both HIV-1 primer/probe sets detect both HIV-1 RNAs but do not detect RNA from the HIV-2 serum, indicating that the HIV-1 primer/probe sets are specific for HIV-1 detection and do not cross- react and detect HIV-2.
- HIV-2 primer/probe set #5 was assessed against RNA isolated from gradient purified HIV-1 as in Example 2. Dilutions of the purified HIV-1 RNA were reverse transcribed, PCR amplified and detected as in Example 2 using HIV-2 consensus primer/probe set #5, with HIV-1 consensus primer/probe set #1 used in separate reactions as a control. The results, shown in Table 1 1 , indicate that HIV-2 primer/probe set #5 does not cross-react and detect HIV-1 RNA. TABLE 11
- HIV-1 and HIV-2 RNA were purified and quantitated as in Examples 2 and 3 respectively.
- the HIV-1 primer/probe set #1 and HIV- 2 primer/probe set #8, which consisted of SEQ ID NOs. 16 and 24 as primers and SEQ ID NO. 18 as probe, prepared as described in Example 1 were used either together or separately to reverse transcribe, amplify and detect the dilutions of purified HIV-1 and HIV-2 RNA as described in Example 2. Results are shown in Table 12. TABLE 12
- MOLECULE TYPE synthetic DNA
- MOLECULE TYPE synthetic DNA
- MOLECULE TYPE synthetic DNA
- MOLECULE TYPE synthetic DNA
- SEQUENCE DESCRIPTION SEQ ID NO : 12 :
- MOLECULE TYPE genomic RNA (HIV-2)
- AAAGATGGAC CAAGACTAAA ACAATGGCCT TTAACAAAAG AAAAAATAGA 400
- AAGCACCTCC AACTAATCCT TATAATACCC CCACATTTGC AATCAAGAAA 500 AAGGACAAAA ACAAATGGAG AATGCTAATA GACTTTAGGG AGCTAAACAA 550
- ACCATCAGTA AACAATGCAG AACCAGGAAA AAGATATATA TACAAAGTCC 750 TACCACAGGG GTGGAAGGGG TCACCAGCAA TTTTTCAATA CACAATGAGG 800
- GAACTAGGCA CTTGGCAAAT GGACTGCACA CATTTAGAAG GAAAAGTCAT 2200 TATAGTAGCA GTACATGTTG CAAGTGGATT TATAGAGGCA GAAGTTATCC 2250
- GAGTGCCTTA CAATCCACAA AGCCAAGGAG TAGTAGAAGC AATGAATCAT 2450 CATCTAAAAA ATCAGATAGA CAGAATTAGA GAGCAGGCAA ATACAGTAGA 2500
- MOLECULE TYPE synthetic DNA
- MOLECULE TYPE synthetic DNA
- SEQUENCE DESCRIPTION SEQ ID NO: 18:
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP50451999A JP3744548B2 (en) | 1997-06-16 | 1998-06-04 | Nucleic acid primers and probes for detecting HIV-1 and HIV-2 |
AT98926340T ATE428809T1 (en) | 1997-06-16 | 1998-06-04 | NUCLEIC ACID PRIMERS AND PROBE FOR DETECTING HIV-1 AND HIV-2 |
CA002292787A CA2292787C (en) | 1997-06-16 | 1998-06-04 | Nucleic acid primers and probes for detecting hiv-1 and hiv-2 |
DE69840743T DE69840743D1 (en) | 1997-06-16 | 1998-06-04 | NUCLEIC ACID PRIMERS AND SENSORS FOR THE DETECTION OF HIV-1 AND HIV-2 |
EP98926340A EP0991782B1 (en) | 1997-06-16 | 1998-06-04 | Nucleic acid primers and probes for detecting hiv-1 and hiv-2 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/876,546 US5962665A (en) | 1997-06-16 | 1997-06-16 | Nucleic acid primers and probes for detecting HIV-1 and HIV-2 |
US08/876,546 | 1997-06-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998058086A2 true WO1998058086A2 (en) | 1998-12-23 |
WO1998058086A3 WO1998058086A3 (en) | 1999-03-11 |
Family
ID=25367981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/011652 WO1998058086A2 (en) | 1997-06-16 | 1998-06-04 | Nucleic acid primers and probes for detecting hiv-1 and hiv-2 |
Country Status (8)
Country | Link |
---|---|
US (2) | US5962665A (en) |
EP (2) | EP2067868B1 (en) |
JP (1) | JP3744548B2 (en) |
AT (1) | ATE428809T1 (en) |
CA (1) | CA2292787C (en) |
DE (1) | DE69840743D1 (en) |
ES (2) | ES2445495T3 (en) |
WO (1) | WO1998058086A2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000029611A2 (en) * | 1998-10-30 | 2000-05-25 | Roche Diagnostics Gmbh | Novel primers and probes for detecting hiv |
EP1026263A2 (en) * | 1999-02-02 | 2000-08-09 | Ortho-Clinical Diagnostics, Inc. | Oligonucleotide reverse transcription primers for efficient detection of HIV-1 and HIV-2 and methods of use thereof |
WO2001007661A2 (en) * | 1999-07-23 | 2001-02-01 | Gen-Probe Incorporated | Polynucleotide amplification method |
WO2001081624A1 (en) * | 2000-04-20 | 2001-11-01 | Virco Bvba | Method for mutation detection in hiv using pol sequencing |
JP2004500840A (en) * | 2000-04-20 | 2004-01-15 | ビルコ・ビーブイビーエイ | Method for detecting mutation in HIV using pol sequence |
EP1430069A2 (en) * | 2001-09-04 | 2004-06-23 | Abbott Laboratories | Amplification and detection reagents for hiv-1 |
WO2006089203A2 (en) * | 2005-02-17 | 2006-08-24 | Istituto Nazionale Per Le Malattie Infettive Irccs Lazzaro Spallanzani | Compositions and methods for detecting viral specific nucleic acids in urine |
US7255996B2 (en) | 2003-12-19 | 2007-08-14 | Gen-Probe Incorporated | Compositions, methods and kits for detecting the nucleic acids of HIV-1 and HIV-2 |
JP2008536481A (en) * | 2005-02-17 | 2008-09-11 | インスティトゥト ナジョネール ペル ル マラッティエ インフェッティヴ イエッレチチエッセ ラッツァーロ スパッランザーニ | Compositions and methods for detecting virus-specific nucleic acids in urine |
US7914982B2 (en) | 2005-02-17 | 2011-03-29 | Trovagene, Inc. | Methods for detecting pathogen specific nucleic acids in urine |
US7973154B2 (en) | 2005-02-17 | 2011-07-05 | Trovagene, Inc. | Kits for diagnosis and monitoring of viral infection by analysis of viral transrenal nucleic acids in urine |
US8486626B2 (en) | 2007-08-22 | 2013-07-16 | Trovagene, Inc. | Methods of detecting cell-free miRNA in urine and blood |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962665A (en) * | 1997-06-16 | 1999-10-05 | Abbott Laboratories | Nucleic acid primers and probes for detecting HIV-1 and HIV-2 |
JP4824236B2 (en) * | 1999-07-09 | 2011-11-30 | ジェン−プローブ・インコーポレーテッド | Detection of HIV-1 by nucleic acid amplification |
US6582920B2 (en) | 2000-09-01 | 2003-06-24 | Gen-Probe Incorporated | Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations |
WO2002034951A2 (en) | 2000-10-23 | 2002-05-02 | Gen-Probe Incorporated | Compositions and methods for detecting human immunodeficiency virus 2 (hiv-2) |
US6770752B2 (en) * | 2001-01-09 | 2004-08-03 | Becton, Dickinson And Company | Sequences for detection of HIV-1 |
US7847087B2 (en) * | 2001-03-05 | 2010-12-07 | Siemens Healthcare Diagnostics Inc. | Methods and primers for evaluating HIV-1 mutations |
JP4301789B2 (en) * | 2001-11-01 | 2009-07-22 | ハウス食品株式会社 | Method for detecting specific plant genera |
JP5479663B2 (en) * | 2002-12-20 | 2014-04-23 | セレラ コーポレーション | Genetic polymorphism associated with myocardial infarction, detection method and use thereof |
EP1602736A1 (en) * | 2004-06-04 | 2005-12-07 | Bio-Rad Pasteur | HIV type and subtype detection |
US7566532B1 (en) | 2004-07-02 | 2009-07-28 | Quest Diagnostics Investments Incorporated | Methods for detecting retroviruses |
EP2742951B1 (en) | 2004-09-14 | 2016-02-03 | Argos Therapeutics, Inc. | Strain independent amplification of HIV polynucleotides |
FR2894673B1 (en) * | 2005-12-14 | 2014-10-31 | Luc Montagnier | METHOD FOR CHARACTERIZING A BIOCHEMICAL ELEMENT HAVING BIOLOGICAL ACTIVITY BY ANALYZING LOW FREQUENCY ELECTROMAGNETIC SIGNALS |
EP2010680A2 (en) * | 2006-04-14 | 2009-01-07 | Tibotec Pharmaceuticals Ltd. | Methods and means for assessing hiv gag/protease inhibitor therapy |
US7833716B2 (en) * | 2006-06-06 | 2010-11-16 | Gen-Probe Incorporated | Tagged oligonucleotides and their use in nucleic acid amplification methods |
JP2010521156A (en) | 2007-03-16 | 2010-06-24 | 454 ライフ サイエンシーズ コーポレイション | System and method for detection of HIV drug resistant variants |
WO2008116184A1 (en) | 2007-03-21 | 2008-09-25 | Applera Corporation | Adaptive thermal block temperature control method and system |
US20080233587A1 (en) * | 2007-03-23 | 2008-09-25 | Applera Corporation | Method for direct amplification from crude nucleic acid samples |
US8153401B2 (en) * | 2007-05-17 | 2012-04-10 | Applied Biosystems, Llc | Method for direct amplification from crude nucleic acid samples |
WO2009017743A2 (en) | 2007-07-30 | 2009-02-05 | Argos Therapeutics, Inc. | Improved primers and probes for the amplification and detection of hiv gag, rev and nef polynucleotides |
SI2294225T1 (en) | 2008-06-30 | 2015-04-30 | Life Technologies Corporation | Method for direct amplification from crude nucleic acid samples |
US8405379B1 (en) | 2008-09-18 | 2013-03-26 | Luc Montagnier | System and method for the analysis of DNA sequences in biological fluids |
US20100136516A1 (en) * | 2008-12-01 | 2010-06-03 | 454 Life Sciences Corporation | System and method for detection of HIV integrase variants |
WO2010144695A1 (en) * | 2009-06-12 | 2010-12-16 | Luc Montagnier | A highly sensitive method for detection of viral hiv dna remaining after antiretroviral therapy of aids patients |
TWI397458B (en) | 2011-05-10 | 2013-06-01 | Apex Mfg Co Ltd | Nail guider and nailing device including the same |
DE102015009439B4 (en) | 2015-07-21 | 2017-07-06 | GFE Blut mbH | Triple Target HIV-1 NAT for detection of all known genotypes |
KR102191513B1 (en) | 2020-02-13 | 2020-12-15 | 주식회사 에스씨엘헬스케어 | A Primer set for HIV-1 drug resistance analysis, a kit comprising the primer set, and analysis method using the same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5599662A (en) * | 1995-02-17 | 1997-02-04 | Hoffmann-La Roche Inc. | Oliconucleotide primers and probes for the detection of HIV-1 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
CA1341423C (en) * | 1984-10-31 | 2003-03-04 | Paul A. Luciw | Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome |
DE3687030T2 (en) | 1985-03-15 | 1993-03-11 | James Summerton | STEREO-REGULAR POLYNUCLEOTID-BINDING POLYMERS. |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4965188A (en) * | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5386022A (en) * | 1985-03-28 | 1995-01-31 | Hoffman-La Roche Inc. | Primes and probes for the amplification and detection of aids associated nucleic acids |
US5306614A (en) * | 1986-01-22 | 1994-04-26 | Institut Pasteur | Methods and kits for diagnosing human immunodeficiency virus type 2(HIV-2) |
US4839288A (en) * | 1986-01-22 | 1989-06-13 | Institut Pasteur | Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes |
OA08468A (en) * | 1986-01-22 | 1988-07-29 | Pasteur Institut | Retrovirus of the HIV-2 type capable of causing AIDS and its antigenic and nucleic components. |
US5310651A (en) * | 1986-01-22 | 1994-05-10 | Institut Pasteur | DNA probes of human immunodeficiency virus type 2 (HIV-2), and methods employing these probes for dectecting the presence of HIV-2 |
AU622426B2 (en) | 1987-12-11 | 1992-04-09 | Abbott Laboratories | Assay using template-dependent nucleic acid probe reorganization |
DE68927025T2 (en) * | 1988-06-14 | 1997-03-27 | Qiagen Gmbh | HIV-2 virus variants |
FR2652091B1 (en) * | 1989-09-20 | 1994-07-22 | Pasteur Institut | NUCLEOTIDE SEQUENCES ARISING FROM THE GENOME OF HIV-1, HIV-2 AND SIV RETROVIRUSES, AND THEIR APPLICATIONS IN PARTICULAR FOR THE AMPLIFICATION OF THE GENOMES OF THESE RETROVIRUSES AND FOR THE IN-VITRO DIAGNOSIS OF INFECTIONS DUE TO THESE VIRUSES. |
FR2647810B1 (en) * | 1989-06-02 | 1994-07-22 | Pasteur Institut | OLIGONUCLEOTIDE PRIMERS FOR THE AMPLIFICATION OF THE GENOME OF HIV-2 AND SIV RETROVIRUSES, AND THEIR APPLICATIONS TO THE IN VITRO DIAGNOSIS OF INFECTIONS DUE TO THESE VIRUSES |
ATE185379T1 (en) * | 1989-06-02 | 1999-10-15 | Pasteur Institut | NUCLEOTIDE SEQUENCES OF THE GENOME OF RETROVIRUSES OF THE TYPES OF HIV-1, HIV-2 AND SIV, THEIR USES FOR THE AMPLIFICATION OF THESE GENOMES AND IN VITRO DIAGNOSIS OF THESE VIRAL INFECTIONS |
AU650622B2 (en) * | 1989-07-11 | 1994-06-30 | Gen-Probe Incorporated | Nucleic acid sequence amplification methods utilizing a transcription complex |
ATE147792T1 (en) * | 1989-11-30 | 1997-02-15 | Pharmacia Biotech Ab | NEW METHOD FOR DETECTING A SPECIFIC NUCLEIC ACID SEQUENCE IN A CELL SAMPLE |
US5629153A (en) * | 1990-01-10 | 1997-05-13 | Chiron Corporation | Use of DNA-dependent RNA polymerase transcripts as reporter molecules for signal amplification in nucleic acid hybridization assays |
DE69131596T2 (en) * | 1990-01-10 | 1999-12-23 | Chiron Diagnostics Corp | DNA-DEPENDENT RNS-POLYMERASE TRANSCRIPTS AS REPORTER MOLECULES FOR SIGNAL ENHANCEMENT IN NUCLEIC ACID HYBRIDIZATION EXAMINATIONS |
US5427930A (en) | 1990-01-26 | 1995-06-27 | Abbott Laboratories | Amplification of target nucleic acids using gap filling ligase chain reaction |
US5587468A (en) * | 1990-06-11 | 1996-12-24 | University Research Corporation | High affinity nucleic acid ligands to HIV integrase |
WO1992016180A2 (en) * | 1991-03-13 | 1992-10-01 | Siska Diagnostics, Inc. | Detection of 3'-azido-3'-deoxythymidine resistance |
DK51092D0 (en) | 1991-05-24 | 1992-04-15 | Ole Buchardt | OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF |
FR2677039B1 (en) * | 1991-05-31 | 1994-09-09 | Cis Bio Int | OLIGONUCLEOTIDES FOR USE AS REAGENTS FOR IN VITRO DETECTION OF HIV TYPE RETROVIRUS INFECTIONS AND METHOD FOR DETECTING HIV TYPE RETROVIRUS. |
US5569582A (en) * | 1991-07-15 | 1996-10-29 | Institute Of Molecular Biology & Technology | Rapid amplification and detection of nucleic acids |
US5464746A (en) | 1991-12-17 | 1995-11-07 | Abbott Laboratories | Haptens, tracers, immunogens and antibodies for carbazole and dibenzofuran derivatives |
US5424414A (en) | 1991-12-17 | 1995-06-13 | Abbott Laboratories | Haptens, tracers, immunogens and antibodies for 3-phenyl-1-adamantaneacetic acids |
ES2267094T3 (en) * | 1991-12-23 | 2007-03-01 | Novartis Vaccines And Diagnostics, Inc. | SET OF HIV PROBES FOR USE IN SANDWICH HYBRIDIZATION TESTS IN DISSOLUTION PHASE. |
WO1994003635A1 (en) * | 1992-08-04 | 1994-02-17 | Institute Of Molecular Biology & Biotechnology | Rapid amplification and detection of nucleic acids |
AU686616B2 (en) * | 1993-03-26 | 1998-02-12 | Gen-Probe Incorporated | Detection of human immunodeficiency virus type 1 |
WO1995014109A1 (en) * | 1993-11-19 | 1995-05-26 | U.S. Department Of The Army | High through-put quantitative polymerase chain reaction for hiv clinical specimens |
US5733781A (en) * | 1994-07-19 | 1998-03-31 | Gen-Probe Incorporated | Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus |
WO1997007235A2 (en) * | 1995-08-14 | 1997-02-27 | Abbott Laboratories | All-in-one nucleic acid amplification assay |
US5962665A (en) * | 1997-06-16 | 1999-10-05 | Abbott Laboratories | Nucleic acid primers and probes for detecting HIV-1 and HIV-2 |
-
1997
- 1997-06-16 US US08/876,546 patent/US5962665A/en not_active Expired - Lifetime
-
1998
- 1998-06-04 ES ES09156276.9T patent/ES2445495T3/en not_active Expired - Lifetime
- 1998-06-04 EP EP09156276.9A patent/EP2067868B1/en not_active Expired - Lifetime
- 1998-06-04 AT AT98926340T patent/ATE428809T1/en not_active IP Right Cessation
- 1998-06-04 WO PCT/US1998/011652 patent/WO1998058086A2/en active Application Filing
- 1998-06-04 JP JP50451999A patent/JP3744548B2/en not_active Expired - Fee Related
- 1998-06-04 CA CA002292787A patent/CA2292787C/en not_active Expired - Fee Related
- 1998-06-04 EP EP98926340A patent/EP0991782B1/en not_active Expired - Lifetime
- 1998-06-04 DE DE69840743T patent/DE69840743D1/en not_active Expired - Lifetime
- 1998-06-04 ES ES98926340T patent/ES2324125T3/en not_active Expired - Lifetime
-
1999
- 1999-10-05 US US09/412,252 patent/US6232455B1/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5599662A (en) * | 1995-02-17 | 1997-02-04 | Hoffmann-La Roche Inc. | Oliconucleotide primers and probes for the detection of HIV-1 |
Non-Patent Citations (6)
Title |
---|
GENE CHARACTERIZATION KITS. THE STRATAGENE CATALOG, 1988 PAGE 39. XP000829524 * |
JOURNAL OF VIROLOGICAL METHODS BOOTMAN ET AL.: 'AN INTERNATIONAL COLLABORATIVE STUDY TO ASSESS A SET OF REFERENCE REAGENTS FOR HIV-1 PCR' vol. 37, 1992, U.K., pages 23 - 42, XP000829523 * |
JOURNAL OF VIROLOGICAL METHODS MONTPETIT ET AL.: 'OLIGSCAN: A COMPUTER PROGRAM TO ASSIST IN THE DESIGN OF PCR PRIMERS HOMOLOGOUS TOO MULTIPE DNA SEQUENCES' vol. 36, 1992, CANADA, pages 119 - 128, XP000829522 * |
LEUKEMIA HUNT ET AL.: 'MOLECULAR ANALYSES OF HIV-1 GROUP O AND HIV-2 VARIANTS FROM AFRICA' vol. 11, no. 3, April 1997, USA, pages 138 - 141, XP000829521 * |
MICHAEL A. INNIS: 'PCR PROTOCOLS', 1990, ACADEMIC PRESS, INC, CALIFORNIA article KELLOGG D.E. ET AL.: 'DETECTION OF HUMAN IMMUNODEFICIECY VIRUS', pages 337 - 347, XP000829544 * |
PROC. NATL. ACAD. SCI. ZAGURI ET AL.: 'GENETIC VARIABILITY BETWEEN ISOLATES OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) TYPE 2 IS COMPARABLE TO THE VAARIABILITY AMONG HIV TYPE 1' vol. 85, August 1988, USA, pages 5941 - 5945, XP000829520 * |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19850186A1 (en) * | 1998-10-30 | 2000-05-25 | Roche Diagnostics Gmbh | New primers and probes for the detection of HIV |
WO2000029611A3 (en) * | 1998-10-30 | 2000-10-26 | Roche Diagnostics Gmbh | Novel primers and probes for detecting hiv |
WO2000029611A2 (en) * | 1998-10-30 | 2000-05-25 | Roche Diagnostics Gmbh | Novel primers and probes for detecting hiv |
EP1026263A2 (en) * | 1999-02-02 | 2000-08-09 | Ortho-Clinical Diagnostics, Inc. | Oligonucleotide reverse transcription primers for efficient detection of HIV-1 and HIV-2 and methods of use thereof |
EP1026263A3 (en) * | 1999-02-02 | 2000-10-11 | Ortho-Clinical Diagnostics, Inc. | Oligonucleotide reverse transcription primers for efficient detection of HIV-1 and HIV-2 and methods of use thereof |
JP2000342274A (en) * | 1999-02-02 | 2000-12-12 | Ortho Clinical Diagnostics Inc | Oligonucleotide reverse transcription primer for efficient detection of hiv-1 and hiv-2 and its use |
US6303293B1 (en) | 1999-02-02 | 2001-10-16 | Ortho-Clinical Diagnostics, Inc. | Oligonucleotide reverse transcription primers for efficient detection of HIV-1 and HIV-2 and methods of use thereof |
KR100901084B1 (en) * | 1999-02-02 | 2009-06-08 | 오르토-클리니칼 다이아그노스틱스, 인코포레이티드 | Oligonucleotide reverse transcription primers for efficient detection of HIV-1 and HIV-2, methods of use thereof and a kit comprising the same |
US6908735B2 (en) | 1999-07-23 | 2005-06-21 | Gen-Probe Incorporated | Polynucleotide quantitation method |
WO2001007661A2 (en) * | 1999-07-23 | 2001-02-01 | Gen-Probe Incorporated | Polynucleotide amplification method |
WO2001007661A3 (en) * | 1999-07-23 | 2002-07-11 | Gen Probe Inc | Polynucleotide amplification method |
WO2001081624A1 (en) * | 2000-04-20 | 2001-11-01 | Virco Bvba | Method for mutation detection in hiv using pol sequencing |
US6800463B1 (en) | 2000-04-20 | 2004-10-05 | Virco Bvba | Method for mutation detection in HIV-1 using pol sequencing |
JP4769403B2 (en) * | 2000-04-20 | 2011-09-07 | ビルコ・ビーブイビーエイ | Method for mutation detection in HIV using pol sequences |
JP2004500840A (en) * | 2000-04-20 | 2004-01-15 | ビルコ・ビーブイビーエイ | Method for detecting mutation in HIV using pol sequence |
US7235387B2 (en) | 2000-04-20 | 2007-06-26 | Virco Bvba | Method for mutation detection in HIV-1 using pol sequencing |
EP1430069A4 (en) * | 2001-09-04 | 2007-04-04 | Abbott Lab | Amplification and detection reagents for hiv-1 |
EP1430069A2 (en) * | 2001-09-04 | 2004-06-23 | Abbott Laboratories | Amplification and detection reagents for hiv-1 |
EP2390259A3 (en) * | 2001-09-04 | 2012-05-02 | Abbott Laboratories | Amplification and detection reagents for HIV-1 |
US7255996B2 (en) | 2003-12-19 | 2007-08-14 | Gen-Probe Incorporated | Compositions, methods and kits for detecting the nucleic acids of HIV-1 and HIV-2 |
US8318432B2 (en) | 2003-12-19 | 2012-11-27 | Gen-Probe Incorporated | Cross-reactive hybridization probe for detecting HIV-1 and HIV-2 nucleic acids in the P31 gene sequence |
US7666600B2 (en) | 2003-12-19 | 2010-02-23 | Gen-Probe Incorporated | Cross-reactive primers for amplifying the nucleic acids of HIV-1 and HIV-2 |
US7973154B2 (en) | 2005-02-17 | 2011-07-05 | Trovagene, Inc. | Kits for diagnosis and monitoring of viral infection by analysis of viral transrenal nucleic acids in urine |
US7914982B2 (en) | 2005-02-17 | 2011-03-29 | Trovagene, Inc. | Methods for detecting pathogen specific nucleic acids in urine |
AU2006214096B2 (en) * | 2005-02-17 | 2011-06-16 | Trovagene, Inc. | Compositions and methods for detecting viral specific nucleic acids in urine |
WO2006089203A3 (en) * | 2005-02-17 | 2007-03-22 | Istituto Naz Per Le Malattie I | Compositions and methods for detecting viral specific nucleic acids in urine |
US7803929B2 (en) | 2005-02-17 | 2010-09-28 | Trovagene, Inc. | Kits for diagnosis and monitoring of pathogenic infection by analysis of cell-free pathogenic nucleic acids in urine |
WO2006089203A2 (en) * | 2005-02-17 | 2006-08-24 | Istituto Nazionale Per Le Malattie Infettive Irccs Lazzaro Spallanzani | Compositions and methods for detecting viral specific nucleic acids in urine |
JP2008536481A (en) * | 2005-02-17 | 2008-09-11 | インスティトゥト ナジョネール ペル ル マラッティエ インフェッティヴ イエッレチチエッセ ラッツァーロ スパッランザーニ | Compositions and methods for detecting virus-specific nucleic acids in urine |
US8383335B2 (en) | 2005-02-17 | 2013-02-26 | Trovagene, Inc. | Method for diagnosis and monitoring of viral infection by analysis of viral transrenal nucleic acids in urine |
CN103045758A (en) * | 2005-02-17 | 2013-04-17 | 特罗瓦基因公司 | Method for diagnosis and monitoring of pathogenic infection by analysis of pathogenic transrenal nucleic acids in urine |
JP2013143946A (en) * | 2005-02-17 | 2013-07-25 | Trovagene Inc | Composition and method for detecting viral specific nucleic acid in urine |
CN101253273B (en) * | 2005-02-17 | 2013-08-28 | 特罗瓦基因公司 | Compositions and methods for detecting viral specific nucleic acids in urine |
US8486626B2 (en) | 2007-08-22 | 2013-07-16 | Trovagene, Inc. | Methods of detecting cell-free miRNA in urine and blood |
Also Published As
Publication number | Publication date |
---|---|
EP2067868A3 (en) | 2009-09-23 |
US5962665A (en) | 1999-10-05 |
DE69840743D1 (en) | 2009-05-28 |
CA2292787A1 (en) | 1998-12-23 |
JP2000512160A (en) | 2000-09-19 |
EP0991782A2 (en) | 2000-04-12 |
US6232455B1 (en) | 2001-05-15 |
WO1998058086A3 (en) | 1999-03-11 |
EP2067868A2 (en) | 2009-06-10 |
JP3744548B2 (en) | 2006-02-15 |
EP2067868B1 (en) | 2013-09-18 |
ES2324125T3 (en) | 2009-07-30 |
CA2292787C (en) | 2009-11-24 |
ES2445495T3 (en) | 2014-03-03 |
ATE428809T1 (en) | 2009-05-15 |
EP0991782B1 (en) | 2009-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6232455B1 (en) | Nucleic acid primers and probes for detecting HIV-1 and HIV-2 | |
EP1076721B1 (en) | Method for using unequal primer concentrations for generating nucleic acid amplification products | |
EP0887427B1 (en) | Amplification and detection of hiv-1 and/or hiv-2 | |
US6475729B1 (en) | Nucleic acid amplification and detection methods using rapid polymerase chain reaction cycle | |
CA2268753C (en) | Nucleic acid primers and probes for detecting oncogenic human papillomaviruses | |
AU781934B2 (en) | Detection of HIV-1 by nucleic acid amplification | |
JP5121777B2 (en) | Assay for detection of human parvovirus B19 nucleic acid | |
EP2390259A2 (en) | Amplification and detection reagents for HIV-1 | |
JP2000342274A (en) | Oligonucleotide reverse transcription primer for efficient detection of hiv-1 and hiv-2 and its use | |
JP4202750B2 (en) | Compositions and methods for detecting human immunodeficiency virus 2 (HIV-2) | |
WO1996040996A1 (en) | Method for detecting nucleic acid sequences using competitive amplification | |
AU2002230545A1 (en) | Compositions and methods for detecting human immunodeficiency virus 2 (HIV-2) | |
CA2257135A1 (en) | Nucleic acid primers and probes for detecting chlamydia pneumoniae | |
EP3830302B1 (en) | Compositions and methods for detecting nucleic acids of epstein-barr virus | |
IE903415A1 (en) | Nucleic acid detection method using unequal primer¹concentrations in polymerase chain reaction | |
CA2374385C (en) | Detection of hiv-1 by nucleic acid amplification |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2292787 Country of ref document: CA Ref country code: CA Ref document number: 2292787 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1999 504519 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998926340 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998926340 Country of ref document: EP |